35 filings
8-K
DRMA
Dermata Therapeutics Inc
7 May 24
Departure of Directors or Certain Officers
5:10pm
8-K
DRMA
Dermata Therapeutics Inc
21 Mar 24
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
DRMA
Dermata Therapeutics Inc
12 Jan 24
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
DRMA
Dermata Therapeutics Inc
17 Nov 23
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
4:06pm
8-K
DRMA
Dermata Therapeutics Inc
15 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:16pm
8-K
464ll0 q6
9 Nov 23
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:08pm
8-K
jwv1okrm
10 Aug 23
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter
4:18pm
8-K
crjw12vn314w jky
3 Aug 23
Changes in Registrant's Certifying Accountant
4:31pm
8-K
uj2ljmlvpn 60lw11
24 May 23
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
5:13pm
8-K
nmd9lykgy 90
11 May 23
Dermata Therapeutics Provides Corporate Update and Reports First Quarter
4:07pm
8-K
2puwq sbo
28 Mar 23
Other Events
4:06pm
8-K
ra4sun5469 uca
20 Mar 23
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
4:36pm
8-K
zso60
13 Mar 23
Material Modifications to Rights of Security Holders
1:16pm
8-K
p2colvtytaa93nbbb
21 Feb 23
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
4:10pm
8-K
myosz
8 Feb 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
viq2fwcgmv lo
15 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
fvhbbywshhz8
5 Dec 22
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
9:01am
8-K
0biofzd
10 Nov 22
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
5:22pm
8-K
xa6cojc
23 Sep 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
4b23h0v2f
15 Aug 22
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:20pm